WVP
AVEO

Worth Venture Partners’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Worth Venture Partners’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-170,925
Closed -$2.56M – 226
2022
Q4 		$2.56M Sell
170,925
-514,101
-75% -$7.12M 1.51% 23
2022
Q3 		$5.64M Sell
685,026
-31,410
-4% -$241K 3.45% 3
2022
Q2 		$4.74M Buy
716,436
+11,282
+2% +$54.6K 2.78% 6
2022
Q1 		$3.94M Buy
705,154
+119,986
+21% +$494K 1.82% 17
2021
Q4 		$2.74M Buy
585,168
+130,804
+29% +$811K 1.36% 27
2021
Q3 		$2.81M Buy
+454,364
New +$2.72M 1.26% 26
2018
Q2 		– Sell
-1
Closed -$24 – 129
2018
Q1 		$0 Buy
+1
New +$29 ﹤0.01% 144

Worth Venture Partners's AVEO Position: Q1 2023 in Review

Worth Venture Partners sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 170,925 shares — an estimated $2.56M sold.

Worth Venture Partners first reported a position in AVEO in Q1 2018 and held it in 7 quarters. The position peaked at $5.64M in Q3 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

  • Worth Venture Partners reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Worth Venture Partners sold 170,925 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $2.56M.
  • Worth Venture Partners first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2018 and held it in 7 quarters.
  • Worth Venture Partners's AVEO Pharmaceuticals, Inc. position peaked at $5.64M in Q3 2022.
  • 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Worth Venture Partners's 13F filing for Q1 2023, filed 15 May 2023.